Description
Orforglipron — an oral, non-peptide GLP-1 receptor agonist — showed cardiovascular safety on a par with insulin glargine in adults with type 2 diabetes at increased cardiovascular risk, according to the phase 3 ACHIEVE-4 trial published in The Lancet.
Read the full research article by Klein and colleagues in The Lancet here: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01865-9/fulltext?dgcid=youtube_video_vabs_lancet_tl
#TheLancet #VideoAbstract #Diabetes #Type2Diabetes #GLP1 #CardiovascularHealth #ClinicalTrial
Visit The Lancet at https://www.thelancet.com/?dgcid=youtube_video_vabs_lancet_tl
* * *
Continue this conversation on social! Follow us today at…
https://bsky.app/profile/thelancet.com
https://Facebook.com/TheLancetMedicalJournal
https://Instagram.com/TheLancetGroup
https://LinkedIn.com/company/The-Lancet